|
[1]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Wu, Z., Bian, T., Dong, C., Duan, S., Fei, H., Hao, D., et al. (2022) Spinal MRI-Based Radiomics Analysis to Predict Treatment Response in Multiple Myeloma. Journal of Computer Assisted Tomography, 46, 447-454. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Morita, K., Karashima, S., Terao, T., Yoshida, K., Yamashita, T., Yoroidaka, T., et al. (2024) 3D CNN-Based Deep Learning Model-Based Explanatory Prognostication in Patients with Multiple Myeloma Using Whole-Body MRI. Journal of Medical Systems, 48, Article No. 30. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Mohan Lal, B., van Rhee, F. and Al Hadidi, S. (2025) Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma. Current Oncology Reports, 27, 258-277. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Soekojo, C.Y., Chung, T., Furqan, M.S. and Chng, W.J. (2022) Genomic Characterization of Functional High-Risk Multiple Myeloma Patients. Blood Cancer Journal, 12, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Caro, J., Al Hadidi, S., Usmani, S., Yee, A.J., Raje, N. and Davies, F.E. (2021) How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book, 41, 291-309. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Dingli, D., Ailawadhi, S., Bergsagel, P.L., Buadi, F.K., Dispenzieri, A., Fonseca, R., et al. (2017) Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 92, 578-598. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
(2024) Chinese Expert Consensus on Diagnosis and Treatment of High Risk Multiple Myeloma. Chinese Journal of Hematology, 45, 430-435.
|
|
[9]
|
Schenone, D., Dominietto, A., Campi, C., Frassoni, F., Cea, M., Aquino, S., et al. (2021) Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. Diagnostics, 11, Article 1759. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Lee, S., Lee, S., Kim, S., Huh, Y., Lee, J., Lee, K., et al. (2023) Differentiating Multiple Myeloma and Osteolytic Bone Metastases on Contrast-Enhanced Computed Tomography Scans: The Feasibility of Radiomics Analysis. Diagnostics, 13, Article 755. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Liu, J., Wang, C., Guo, W., Zeng, P., Liu, Y., Lang, N., et al. (2021) A Preliminary Study Using Spinal MRI-Based Radiomics to Predict High-Risk Cytogenetic Abnormalities in Multiple Myeloma. La Radiologia Medica, 126, 1226-1235. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wennmann, M., Ming, W., Bauer, F., Chmelik, J., Klein, A., Uhlenbrock, C., et al. (2023) Prediction of Bone Marrow Biopsy Results from MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics. Investigative Radiology, 58, 754-765. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Huang, L., Zhao, Z., An, L., Gong, Y., Wang, Y., Yang, Q., et al. (2024) 2.5D Transfer Deep Learning Model for Segmentation of Contrast-Enhancing Lesions on Brain Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis OPTICA Spectrum Disorder. Quantitative Imaging in Medicine and Surgery, 14, 273-290. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Zhang, Y., Chen, Z., Bu, Y., Lei, P., Yang, W. and Zhang, W. (2024) Construction of a 2.5D Deep Learning Model for Predicting Early Postoperative Recurrence of Hepatocellular Carcinoma Using Multi-View and Multi-Phase CT Images. Journal of Hepatocellular Carcinoma, 11, 2223-2239. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Liu, S., Liu, C., Pan, H., Li, S., Teng, P., Li, Z., et al. (2025) Magnetic Resonance Imaging-Based Nomograms Predict High-Risk Cytogenetic Abnormalities in Multiple Myeloma: A Two-Centre Study. Clinical Radiology, 82, Article 106768. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Kumar, S.K., Jacobus, S.J., Cohen, A.D., Weiss, M., Callander, N., Singh, A.K., et al. (2020) Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 1317-1330. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Rajkumar, S.V. (2024) Multiple Myeloma: 2024 Update on Diagnosis, Risk-Stratification, and Management. American Journal of Hematology, 99, 1802-1824. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Facon, T., Venner, C.P., Bahlis, N.J., Offner, F., White, D.J., Karlin, L., et al. (2021) Oral Ixazomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 137, 3616-3628. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Mateos, M., Cavo, M., Blade, J., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., et al. (2020) Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 395, 132-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Callander, N.S., Baljevic, M., Adekola, K., Anderson, L.D., Campagnaro, E., Castillo, J.J., et al. (2022) NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20, 8-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Smith, S.C., Althof, P.A., Dave, B.J. and Sanmann, J.N. (2020) High-Risk Cytogenetics in Multiple Myeloma: Further Scrutiny of Deletions within the IGH Gene Region Enhances Risk Stratification. Genes, Chromosomes and Cancer, 59, 569-574. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kumar, S.K., Rajkumar, V., Kyle, R.A., van Duin, M., Sonneveld, P., Mateos, M., et al. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Cowan, A.J., Green, D.J., Kwok, M., Lee, S., Coffey, D.G., Holmberg, L.A., et al. (2022) Diagnosis and Management of Multiple Myeloma. JAMA, 327, 464-477. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Zamagni, E., Tacchetti, P. and Cavo, M. (2019) Imaging in Multiple Myeloma: How? When? Blood, 133, 644-651. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hillengass, J., Fechtner, K., Weber, M., Bäuerle, T., Ayyaz, S., Heiss, C., et al. (2010) Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients with Asymptomatic Multiple Myeloma. Journal of Clinical Oncology, 28, 1606-1610. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Litjens, G., Kooi, T., Bejnordi, B.E., Setio, A.A.A., Ciompi, F., Ghafoorian, M., et al. (2017) A Survey on Deep Learning in Medical Image Analysis. Medical Image Analysis, 42, 60-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Truhn, D., Schrading, S., Haarburger, C., Schneider, H., Merhof, D. and Kuhl, C. (2019) Radiomic versus Convolutional Neural Networks Analysis for Classification of Contrast-Enhancing Lesions at Multiparametric Breast MRI. Radiology, 290, 290-297. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Staartjes, V.E., de Wispelaere, M.P., Vandertop, W.P. and Schröder, M.L. (2019) Deep Learning-Based Preoperative Predictive Analytics for Patient-Reported Outcomes Following Lumbar Discectomy: Feasibility of Center-Specific Modeling. The Spine Journal, 19, 853-861. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Mohsen, F., Ali, H., El Hajj, N. and Shah, Z. (2022) Artificial Intelligence-Based Methods for Fusion of Electronic Health Records and Imaging Data. Scientific Reports, 12, Article No. 17981. [Google Scholar] [CrossRef] [PubMed]
|